Janus Capital Management LLC cut its stake in Edge Therapeutics, Inc. (NASDAQ:EDGE) by 2.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,115,566 shares of the biotechnology company’s stock after selling 47,944 shares during the period. Janus Capital Management LLC owned about 6.87% of Edge Therapeutics worth $19,272,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. State Street Corp raised its stake in Edge Therapeutics by 5.7% in the fourth quarter. State Street Corp now owns 200,301 shares of the biotechnology company’s stock valued at $2,505,000 after buying an additional 10,859 shares in the last quarter. Teachers Advisors LLC raised its stake in Edge Therapeutics by 8.2% in the fourth quarter. Teachers Advisors LLC now owns 28,353 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 2,150 shares in the last quarter. Regentatlantic Capital LLC acquired a new stake in Edge Therapeutics during the first quarter valued at approximately $1,230,000. Wells Fargo & Company MN raised its stake in Edge Therapeutics by 1.7% in the first quarter. Wells Fargo & Company MN now owns 11,942 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 200 shares in the last quarter. Finally, TFS Capital LLC acquired a new stake in Edge Therapeutics during the first quarter valued at approximately $209,000. Institutional investors and hedge funds own 48.72% of the company’s stock.

Edge Therapeutics, Inc. (NASDAQ:EDGE) traded down 2.63% on Thursday, reaching $10.36. 70,444 shares of the company’s stock were exchanged. The stock’s market capitalization is $319.63 million. Edge Therapeutics, Inc. has a 1-year low of $7.30 and a 1-year high of $13.50. The firm’s 50 day moving average is $10.30 and its 200 day moving average is $9.79.

Edge Therapeutics (NASDAQ:EDGE) last released its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.44). Analysts expect that Edge Therapeutics, Inc. will post ($1.87) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/03/janus-capital-management-llc-sells-47944-shares-of-edge-therapeutics-inc-nasdaqedge-updated-updated-updated.html.

Separately, BidaskClub upgraded shares of Edge Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday.

In other Edge Therapeutics news, insider Brian A. Leuthner sold 7,500 shares of the firm’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $10.19, for a total transaction of $76,425.00. Following the completion of the sale, the insider now directly owns 132,736 shares in the company, valued at approximately $1,352,579.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 36.19% of the company’s stock.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Institutional Ownership by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Stock Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related stocks with our FREE daily email newsletter.